title: [Effects of Naoxinduotai capsule on markers of prothrombotic state in patients with essential hypertension].
abstract: OBJECTIVE
  To investigate the effects of Naoxinduotai capsule on the markers of prothrombotic state as plasminogen activator inhibitor-1 (PAI-1), von Willebrand factor (vWF) and alpha-granular membrane protein (CD62p) in essential hypertension patients of yang hyperactivity and blood stagnation.
  
  
  METHODS
  The 62 essential hypertension patients of yang hyperactivity and blood stagnation were divided into Naoxinduotai capsule + perindopril group (treatment group, 30 subjects) and Perindopril group (control group, 32 subjects). Clinical symptoms, blood pressure and the blood plasma PAI-1, vWF, CD62p of the patients were observed. The blood plasma PAI-1, vWF and CD62p were measured by enzyme-linked immunosorbant assay (ELISA).
  
  
  RESULTS
  After 8 weeks treatment, in treatment group the clinical symptoms became better, and there was a significant difference with control group (P < 0.05). Blood pressure was significantly degraded, but there was not a significant difference with control group. The blood plasma PAI-1, vWF, CD62p level was degraded ,and there were significant differences with control group in all the three makers (P < 0.05).
  
  
  CONCLUSIONS
  Naoxinduotai capsule can treat the essential hypertension patients of Yang hyperactivity and blood stagnation, and it has conspicuous advantages in improving the clinical symptoms and the makers of prothrombotic state.
authors: Xuhui District Central Hospital of Shanghai, Shanghai 200031, China.
authors: Jianmei
authors: J
authors: Yang
authors: Guoyin
authors: G
authors: Wang
authors: Youhua
authors: Y
authors: Wang
authors: Suyun
authors: S
authors: Yuan
authors: Duan
authors: D
authors: Zhou
mesh_terms: D000368:Aged; D015415:Biomarkers / Q000097:blood; D001794:Blood Pressure / Q000187:drug effects; D002214:Capsules; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D019007:P-Selectin / Q000097:blood; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood; D010980:Platelet Membrane Glycoproteins / Q000378:metabolism; D013927:Thrombosis / Q000097:blood*; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D002214:Capsules; D019007:P-Selectin; D017395:Plasminogen Activator Inhibitor 1; D010980:Platelet Membrane Glycoproteins; C028254:von Willebrand factor receptor